TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P 1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic ...

With our current indications, adults with painful diabetic peripheral neuropathy of the feet and postherpetic neuralgia ... have been reported following administration of QUTENZA. Assess for signs of ...

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

"The completion of enrollment is an exciting milestone. With our current indications, adults with painful diabetic peripheral neuropathy of the feet and postherpetic neuralgia, we have advanced the ...